login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
PROTAGONIST THERAPEUTICS INC (PTGX) Stock News
USA
-
Nasdaq
- NASDAQ:PTGX -
US74366E1029
-
Common Stock
85.64
USD
-4.36 (-4.84%)
Last: 12/1/2025, 8:00:00 PM
85.64
USD
0 (0%)
After Hours:
12/1/2025, 8:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PTGX Latest News, Press Relases and Analysis
All
Press Releases
4 days ago - By: The Motley Fool
Protagonist (PTGX) Earnings Call Transcript
5 days ago - By: ACCESS Newswire
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
25 days ago - By: Zacks Investment Research
- Mentions:
ADCT
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates
25 days ago - By: ACCESS Newswire
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
a month ago - By: Zacks Investment Research
- Mentions:
BOLT
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?
a month ago - By: ACCESS Newswire
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
a month ago - By: Benzinga
What 7 Analyst Ratings Have To Say About Protagonist Therapeutics
2 months ago - By: Stocktwits
- Mentions:
JNJ
BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In
a month ago - By: Zacks Investment Research
- Mentions:
MNKD
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?
a month ago - By: ACCESS Newswire
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
a month ago - By: The Motley Fool
- Mentions:
GTLS
BXS
PIPR
INDB
...
Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million
2 months ago - By: Benzinga
5 Analysts Assess Protagonist Therapeutics: What You Need To Know
3 months ago - By: ACCESS Newswire
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
2 months ago - By: Stocktwits
- Mentions:
JNJ
LEGN
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print
2 months ago - By: Zacks Investment Research
- Mentions:
JNJ
PFE
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
2 months ago - By: Bloomberg
- Mentions:
JNJ
Johnson & Johnson in Talks to Buy Protagonist Therapeutics: WSJ
2 months ago - By: ACCESS Newswire
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
3 months ago - By: ACCESS Newswire
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
3 months ago - By: ACCESS Newswire
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
3 months ago - By: ACCESS Newswire
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
3 months ago - By: ACCESS Newswire
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Please enable JavaScript to continue using this application.